Introduction
============

There has been a dramatic increase in the prevalence of allergic diseases, which are common and frequently present in clinical practice ([@b1-mmr-20-06-5324],[@b2-mmr-20-06-5324]). *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae* are the major house dust mite (HDM) species, and are the most significant sources of indoor allergens for inhalation, causing allergic diseases, including allergic asthma and allergic rhinitis atopic dermatitis ([@b3-mmr-20-06-5324],[@b4-mmr-20-06-5324]). Desensitization treatment with HDM extracts is currently one of the most effective treatments against allergies to HDMs ([@b5-mmr-20-06-5324]). However, it is difficult to ensure the consistency of the natural extracts of HDMs because of their complex components, including inflammatory molecules (ceramides, kallikreins and endotoxin), that are usually responsible for side effects and poor efficacy ([@b6-mmr-20-06-5324]). Therefore, recombinant allergens are given prior to their natural counterparts in HDM-specific immunotherapy to improve the efficacy and safety of presentation, diagnosis and clinical immunotherapy ([@b7-mmr-20-06-5324]).

Decades of research have revealed and characterized \>30 different allergens in *D. farinae*; group 1 and group 2 allergens are the most clinically relevant, as they possess IgE-binding activity in \>80% of patients with HDM allergies ([@b8-mmr-20-06-5324]--[@b10-mmr-20-06-5324]). These allergens induce T helper 2 immune responses by encoding cysteine proteases and epididymal proteins ([@b9-mmr-20-06-5324],[@b11-mmr-20-06-5324]). Translation elongation factors (TEFs) are expressed in Cladosporium, Rubber and HDM ([@b12-mmr-20-06-5324]--[@b14-mmr-20-06-5324]). The allergenicity of the TEF 2 in *D. farinae* has not been defined. Therefore, understanding the allergenicity of TEF 2 will be important for the detection and treatment of allergic responses.

Currently, with the development of bioinformatics, the concept of precision medicine is emerging. Bioinformatics can predict key target spots of a disease, which can provide critical references for the drug and therapy development ([@b15-mmr-20-06-5324],[@b16-mmr-20-06-5324]). Previously, epitope peptide vaccines were considered to have excellent potential application prospects, therefore, it is critical to predict the epitope of novel allergens ([@b17-mmr-20-06-5324]--[@b19-mmr-20-06-5324]). Novel vaccines, synthesized based on B-cells of the T-cell epitope, can activate the produce specific antibodies from human B cells, and can also eliminate infected cells by activating cytotoxic lymphocytes ([@b17-mmr-20-06-5324]). Therefore, the present study cloned, expressed and purified TEF 2, and evaluated its allergenicity. The properties of TEF 2 were predicted by using bioinformatics tools, providing valuable information for further vaccine development.

Materials and methods
=====================

### Sera and skin prick test (SPT)

The written informed consent was obtained from each participant for the use of peripheral blood samples and SPT. The serum and SPT of 37 allergic patients (22 female, 15 male; 8--86 years) were from The First Affiliated Hospital of Guangzhou Medical University. The sera of 3 healthy subjects (3 male, 8--15 years) were recruited from Shenzhen Children\'s Hospital. The 11 children among the subjects were approved by legal guardians. The samples were collected between January 2014 and December 2015. the present study was approved by the ethic Committee of the Institutional Review Board of the School of Medicine, Shenzhen University.

### Obtaining the gene encoding TEF 2

In a previous study, the draft genome of *Dermatophagoides farinae* were assembled using high-throughput sequencing ([@b20-mmr-20-06-5324]). The gene sequence of Der f TEF 2 was obtained by high-throughput sequencing from *Dermatophagoides farinae* (Hong Kong Bioinformatics Centre, Hong Kong) and then the gene of Der f TEF 2 was synthesizing by Sangon Biotech in Shanghai. The 18 µl cDNA mixed with 2 µl (1/10 volume) of 10X DNA loading buffer (Beijing Solarbio Science & Technology Co., Ltd.) were added to the sample tank and the electrophoresis started. After the electrophoresis, the gel was stained by ethidium bromide, and images were captured under a UV lamp with a wavelength of 302 nm.

### Expression and purification of recombinant TEF 2

The cDNA of Der f TEF 2 was inserted into a pMD-18T vector (Takara Bio, Inc.), cloned into the *Bam*HI and *Hind*III sites and the plasmids were heat-transformed into *E. coli* Top10 (Invitrogen; Thermo Fisher Scientific, Inc. The bacteria were incubated in LB medium (Beijing Solarbio Science & Technology Co., Ltd.) with 100 mg/l ampicillin and cultured overnight at 37°C. The recombinant colonies were transferred into LB medium with ampicillin to expand the culture, followed by plasmid extraction using plasmid DNA extraction kit (Omega Bio-Tek, Inc). The recombinant plasmid was characterized using *Bam*HI and sequenced by BGI Group. After sequencing, the correct clone was ligated into the pET-32a expression vector (Novagen; Merck KGaA) at 37°C for 4 h. Initial cloning was performed with the *E. coli* strain Top10 cultured overnight at 37°C; a single colony was picked, and the plasmid was extracted for identification using *Bam*HI and *Hind*III restriction enzymes. pET-32a-TEF 2 was transformed into *E. coli* BL21 (Invitrogen; Thermo Fisher Scientific, Inc.) cells for expression. The cells were grown in LB medium supplemented with 50 µg/ml ampicillin until the logarithmic phase was reached (A600 nm =0.6--0.9). Expression of TEF 2 was induced by adding 20 µl of isopropyl-D-thiogalactopyranoside (IPTG; 1 mol/l) to the LB medium. After 4 h of continued incubation at 37°C, the bacteria were harvested via centrifugation at 11,180 × g at room temperature for 5 min and 1 ml of the bacterial culture resuspended in 100 µl deionized water and mixed with 20--25 µl 10X protein SDS-PAGE loading buffer (Beijing Solarbio Science & Technology Co., Ltd.). The expression of the recombinant proteins was analyzed using 12% SDS-PAGE electrophoresis.

Following the induced expression of the recombinant protein, the samples were lysed using ultrasonic treatment at 4°C and an amplitude of 38% for 5 min (1 sec pulse on and 0.1 sec pulse off). The supernatant was purified using a balanced Ni-NTA column (ShangHai, Sangon Biotech, cat. no. C600792, 5 ml, 90 µm) at a speed of 2 ml/min and 4°C. After washing with a washing buffer (50 mM Tris, 40 mM imidazole and 0.5 M NaCl, pH 8), the protein was eluted slowly using an elution buffer (50 mM Tris, 0.3 M imidazole and 0.2 M NaCl, pH 8). The elution peak was collected by elution buffer (50 mM Tris, 0.3 M imidazole and 0.2 M NaCl, pH 8).

### ELISAs

The HDMs allergic sera IgE antibodies specific to TEF 2 were measured indirectly using ELISAs. Briefly, 96-well microtiter plates were coated with 100 ng/well of TEF 2 at a concentration of 1 µg/ml in carbonate buffered solution (15 mM Na~2~CO~3~ and 35 mM NaHCO~3~, pH 9.5) at 4°C overnight and then blocked with 200 µl 3% BSA in PBS at 37°C for 120 min. Each well was prepared with the serum (diluted 1:5; 100 µl/well) as the primary antibody or 3% BSA (as a negative control, Beijing Solarbio Science & Technology Co., Ltd.) and incubated at 37°C for 60 min. The plates were incubated with peroxidase-conjugated goat anti-human IgE (1:2,000, A18793, Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 60 min. Each incubation step was followed by three washes with PBS-0.05% Tween 20 (PBST). Color was developed by adding 100 µl/well TMB at 37°C for 10 mins and terminated by the addition of 2 M H2SO4 (50 µl/well). Absorbance was determined using a microplate reader at 450 nm.

### Determination of inhibition using ELISA

The serum of patients allergic to TEF 2 was used for inhibition experiments to determine the cross reactivity among TEF 2 and HDMs. Patients\' sera (supplied pre-diluted in 2% BSA in PBST) were pre-incubated with purified Der f TEF 2 or dust mite extract (DME) obtained from mites that were cryopreserved in liquid nitrogen and then ground to a powder (final concentration: 0.00001, 0.0001, 0.001, 0.01 or 1 g/ml) at 4°C overnight. Pre-incubated Der f TEF 2 or DME as the primary antibody were added to the microtiter plates pre-coated with TEF 2 or DME (0.1 µg/well) and the ELISA was performed as in the previous section. According to ELISA test procedures, data from three experiments were collected. The inhibition rates were calculated according to the following formula: Inhibition (%)=(OD~0~-OD~inhibitor~)/(OD~0~-OD~BSA~), where: OD~0~=the optical density of antigen without any inhibitor, OD~inhibitor~=the optical density after adding an inhibitor (0.00001, 0.0001, 0.001, 0.01 or 1 g/ml TEF2 or DME), and OD~BSA~=the optical density with only BSA in the plate.

### SPT of recombinant TEF 2

SPTs were performed with purified and endotoxin-removed TEF 2 (0.01 mg/ml). dissolved in phosphate buffer (pH 7.4, 50 mM phosphate buffer, 100 mM NaCl). Glycerin was added to a final concentration of 50%. The sample contained histamine phosphate (5 mg/ml) as the positive control or saline as a negative control. The results were checked 20 min after the SPT. The results were classified as follows: The prick spot became a wheal and fleck surrounding the wheal, it was positive (+); 3+, the response was the same as or stronger that of the histamine control; 2+, the response was weaker than that of the histamine control but stronger than that of the negative control; 1+, the response was significantly weaker than that of the histamine control but slightly stronger than that of the negative control; negative, no response ([@b21-mmr-20-06-5324]).

### Analysis of immunogenicity by immunoblotting

SPTs and sera from non-allergic children were used to assess immunogenicity. TEF 2 was subjected to 12% SDS-PAGE and transferred to a nitrocellulose membrane for immunoblot analysis. The membrane was blocked with 3% BSA for 1 h at 37°C and incubated with SPTs and sera from non-allergic children (diluted 1:5 with 5% BSA-PBST, PBST: PBS containing 0.05% Tween 20; 100 µl/well) for 1 h at room temperature. After washing five times with TBST, the membrane was incubated with a secondary antibody (peroxidase-conjugated goat anti-human IgE, 1:2,000, A18793, Invitrogen; Thermo Fisher Scientific, Inc.) for 1 h at 37°C. Finally, after washing three times with TBS-T, the membrane was developed with a DAB kit (Invitrogen; Thermo Fisher Scientific, Inc.).

### Bioinformatics analysis of TEF 2

The open reading frame (ORF) of TEF 2 was analyzed using the NCBI database (<http://www.ncbi.nlm.nih.gov/>), its physicochemical properties were predicted using the ProtParam Tool (<http://web.expasy.org/protparam/>), and the amino acid sequence was predicted using the Translate Tool (<http://web.expasy.org/translate/>) ([@b22-mmr-20-06-5324],[@b23-mmr-20-06-5324]). NetPhos3.1 (<http://www.cbs.dtu.dk/services/NetPhos/>) was used to predict phosphorylation sites, and Subcellular localization of cathepsin D was predicted by CELLO 2.5 ([@b24-mmr-20-06-5324]). ProtScale (<http://web.expasy.org/protscale/>) was used to assess the hydrophilicity, average flexibility and the relative mutability ([@b25-mmr-20-06-5324],[@b26-mmr-20-06-5324]). Secondary structural elements were obtained using DNAStar. InterPro5.0 (<http://www.ebi.ac.uk/interpro/>), ScanProsite (<http://prosite.expasy.org/scanprosite/>) and MotifScan (<http://myhits.isb-sib.ch/cgi-bin/motif_scan>) was used to assess functional sites. The phylogenetic tree was constructed using BLAST, MEGA 5.0 and ClustalX 2.1 software ([@b27-mmr-20-06-5324]). The Bioinformatics Predicted Antigenic Peptides (BPAP) system (<http://imed.med.ucm.es/Tools/antigenic.pl>), DNAStar Protean system (DNAStar Inc, Madison, WI, USA) and the BepiPred 1.0 server (<http://www.cbs.dtu.dk/services/BepiPred/>) were used to predict the B cell epitopes of TEF 2 ([@b28-mmr-20-06-5324]--[@b30-mmr-20-06-5324]). Furthermore, the Immune Epitope Database, Propre, SYFPEITHI, Net-MHCII 2.2 server and NetMHCIIpan-3.0 server were used to study the T cell epitopes of Der f TEF 2 ([@b28-mmr-20-06-5324]--[@b30-mmr-20-06-5324]).

### Statistical analysis

All data are presented as the mean ± SD and analyzed SPSS 18.0 statistical software (SPSS, Inc.). Student\'s t-test was used for the mean differences between two groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Synthesizing and analysis of amino acid sequence homology, alignment and molecular evolution

The cDNA of Der f TEF 2 showed bright bands at \~2,000 bp after double enzymatic digestion ([Fig. 1A](#f1-mmr-20-06-5324){ref-type="fig"}). The sequencing results showed that one ORF of Der f TEF 2 is 2,535 bp long and encodes 844 amino acids from the ATG start codon to the TAA stop codon ([Fig. 1B](#f1-mmr-20-06-5324){ref-type="fig"}). Alignment between Der f TEF 2 and the homologous amino acid sequences from different species of Insecta, Merostomata and Arachnida was conducted using BLAST. Der f TEF 2 is 94, 93 and 87% similar to *Sarcoptes scabiei* (GenBank: KPM11996.1), *Rhagoletis zephyria* (GenBank: XP_017490130.1) and *Galendromus occidentalis* (GenBank: XP_003744110.1), respectively, indicating high homology ([Fig. 2A](#f2-mmr-20-06-5324){ref-type="fig"}). The homologous sequence was output in FASTA format after using MEGA 5.0 and ClustalX 2.1 software to construct the molecular evolutionary tree. The results showed that the TEF 2 gene from Der f has a relatively close relationship with the TEF 2 gene from *Lasius niger, D. farina, Camponotus floridanus, Harpegnathos saltator, Melipona quadrifasciata* and *Sarcoptes scabiei* ([Fig. 2B](#f2-mmr-20-06-5324){ref-type="fig"}).

### Immunogenicity of recombinant TEF 2

The SDS-PAGE analysis showed that TEF 2 was successfully expressed had a molecular weight of \~100 kDa as predicted ([Fig. 3A](#f3-mmr-20-06-5324){ref-type="fig"}). To determine the allergenicity of recombinant TEF 2, immunoblot analysis was used to determine if the recombinant protein could react with serum from patients that are allergic to HDMs; the IgE-binding band had a molecular weight of \~100 kDa as predicted ([Fig. 3B](#f3-mmr-20-06-5324){ref-type="fig"}). The serum IgE from patients allergic to HDMs that was bound by recombinant TEF 2 was \>6-fold higher compared with the serum IgE from healthy controls when quantified via ELISA ([Fig. 3C](#f3-mmr-20-06-5324){ref-type="fig"}). For ELISA inhibition assays, dilutions of recombinant TEF 2 or DME were incubated with the serum. The incubation inhibited the IgE binding of the serum obtained from patients to the coated DME or recombinant TEF 2 in a dose-dependent manner. The inhibition rate of recombinant TEF 2 against DME was \~60% at 0.1 mg/ml ([Fig. 3D](#f3-mmr-20-06-5324){ref-type="fig"}). These results suggested that TEF 2 may be a novel allergen from the HDM allergen family that leads to type I hypersensitivity.

### Clinical SPTs

SPTs were performed with Der f TEF2 in 37 patients sensitized to HDMs; 6 patients (16.2%) showed a positive reaction ([Table I](#tI-mmr-20-06-5324){ref-type="table"}).

### Structural and functional prediction

As shown, there was no cleavage site in the amino acid sequence as predicted using SignalP 4.1 ([Fig. 4A](#f4-mmr-20-06-5324){ref-type="fig"}). Prediction of the physicochemical properties of Der f TEF 2 using the ProtParam Tool estimated that the molecular formula was C~4,216~H~6,703~N~1,141~O~1,240~S~47~, with a molecular weight of 94,722.32 Da and a theoretical isoelectric point of 6.25. The grand average of hydrophobicity (GRAVY) was predicted to be −0.222, the aliphatic index was 87.86 and the instability index was predicted to be 34.13. According to the definition provided by ProtParam, when the instability coefficient is \<40, the protein is predicted to be stable; therefore, the TEF 2 protein was classified as stable. Combined with the analysis from the ProtScale software scale 'Hphob./Kyte & Doolittle', these results indicated the hydrophilicity of the protein. It showed that the most hydrophilic site of Der f TEF 2 appeared at amino acid position 62 with a score of −3.3456, and the most hydrophobic site appeared at amino acid position 132 with a score of 2.333 ([Fig. 4B](#f4-mmr-20-06-5324){ref-type="fig"}). The maximum score for the average flexibility was calculated to be 0.501 at amino acid position 706; the minimum score at amino acid position 481 was 0.376 ([Fig. 4C](#f4-mmr-20-06-5324){ref-type="fig"}). The relative mutability was calculated to have a maximum score of 103.000 at amino acid position 191; the minimum score, at amino acid position 716, was 47.889 ([Fig. 4D](#f4-mmr-20-06-5324){ref-type="fig"}). Using the Polarity/Zimmerman scale, the individual values were scored at a maximum of 39.766 at residue 62 and at a minimum of 0.237 at residue 745 ([Fig. 4E](#f4-mmr-20-06-5324){ref-type="fig"}). The accessible residues (%) were calculated as a minimum score of 3.478 at residues 279 and 280, and a maximum score of 7.900 at residues 314--316 ([Fig. 4F](#f4-mmr-20-06-5324){ref-type="fig"}).

NetPhos3.1 identified 31 phosphorylation sites. In total, 17 Ser residues (23, 41, 76, 97, 109, 116, 211, 214, 264, 391, 404, 488, 564, 570, 573, 664 and 833), 8 Thr residues (59, 69, 298, 390, 473, 558, 568, and 824) and 6 Tyr residues (179, 271, 359, 420, 443 and 840) were identified as potential phosphorylation sites ([Fig. 5](#f5-mmr-20-06-5324){ref-type="fig"}). The secondary structure prediction of Der f TEF 2 with DNAStar predicted 27 α-helices and 6 β-sheets in the protein ([Fig. 5](#f5-mmr-20-06-5324){ref-type="fig"}). The subcellular localization of Der f TEF 2 was predicted to be in the plasma membrane and extracellular space ([Table II](#tII-mmr-20-06-5324){ref-type="table"}). Moreover, Der f TEF 2 was predicted to be a P-loop-containing nucleoside triphosphate hydrolase, Translation protein family member with G_TR_2 and G_TR_1 peptidase domains ([Table III](#tIII-mmr-20-06-5324){ref-type="table"}).

BPAP, DNAStar Protean and BepiPred 1.0 were used to predict the B cell epitopes of Der f TEF 2. The hydrophilicity, surface accessibility and flexibility of proteins play an important role in the formation of antigens. When the hydrophilic score is \>0, the antigen index is \>0 and surface accessibility is \>l, an epitope is likely to be formed. Consolidating the predictions of these three tools, 17 potential B cell epitopes were identified on Der f TEF 2 (amino acids 29--35, 55--64, 92--99, 173--200, 259--272, 311--318, 360--365, 388--395, 422--428, 496--502, 512--518, 567--572, 580--586, 602--617, 785--790, 811--817 and 827--836; [Fig. 5](#f5-mmr-20-06-5324){ref-type="fig"}). The SYFPEITHI, NetMHCII 2.2 server, NetMHCIIpan-3.0 server, Immune Epitope Database and Propred were applied to predict the T cell epitopes of Der f TEF 2. Based on the results of these five immunoinformatics tools, the potential epitopes of Der f TEF 2 were predicted to comprise 14 peptide sequences (amino acids 1--15, 65--79, 120--134, 144--159, 236--250, 275--289, 404--418, 426--440, 463--477, 510--524, 644--658, 684--698, 716--730 and 816--830; [Table IV](#tIV-mmr-20-06-5324){ref-type="table"} and [Fig. 5](#f5-mmr-20-06-5324){ref-type="fig"}).

Discussion
==========

The present study used high-throughput sequencing analysis of the HDM genome and transcriptome to study an HDM gene that may be involved in the allergic response ([@b20-mmr-20-06-5324]). Previous studies have shown that HDM allergens are diverse, and numerous mite allergens have not been completely identified or characterized ([@b31-mmr-20-06-5324]). The identification and characterization of novel HDM allergens may promote the development of improved diagnostic tools and immunotherapeutic vaccines. TEF 2 is one of the most abundant proteins in eukaryotes and plays an important role in various cellular processes, such as the regulation of cellular energy metabolism and apoptosis ([@b32-mmr-20-06-5324],[@b33-mmr-20-06-5324]). It has been reported that Rubber Elongation Factor is the major allergen in latex gloves, and triggers occupational latex allergy in an increasing number of healthcare workers and patients ([@b34-mmr-20-06-5324]). The genes of Der f TEF 2 are highly conserved among different species, indicating that there is cross-reactivity for this protein. Thus, it was important to investigate the allergenicity of TEF 2 in *D. farinae*.

In the present study, Der f TEF 2 was identified and characterized as a novel allergen from *D. farinae* via cloning and expression of the recombinant protein. The recombinant Der f TEF 2 is encoded by a 2,535-bp ORF that produces a predicted sequence of 844 amino acids. Using a SPT, Der f TEF 2 was shown to be an important allergen and was found to react with the sera from 16.2% of patients sensitized to HDMs. Furthermore, it was found that the serum IgE from patients allergic to HDMs bound to the recombinant TEF 2 protein and that the 6 patients with positive SPT results showed high levels of recombinant TEF2-specific IgE in the sera, as determined by ELISA and immunoblotting. Immune inhibition assays showed IgE cross-reactivity between recombinant Der f TEF 2 and DME. These results suggested that Der f TEF 2 is a novel type of allergen from HDMs.

Bioinformatics is an important technique for predicting the corresponding sequences, structures, functional properties and allergenicity of proteins ([@b35-mmr-20-06-5324]). In the present study, the amino acid physicochemical parameters, homology, phosphorylation sites, secondary structure, and the T cell and B cell epitopes of Der f TEF 2 were analyzed via bioinformatics tools. The predicted results showed that Der f TEF 2 is highly homologous to various insect species, contains 17 serine, 8 threonine and 6 tyrosine residues that are potential phosphorylation sites, and is a relatively stable protein. Using the software DNAStar to predict the secondary structure of TEF 2, it was found that there are 27 α-helices and 5 β-sheets folds within the protein. In addition to these indices, the average flexibility, relative mutability, polarity and the accessible residues were determined using ProtScale tools. These bioinformatic characterizations will facilitate the understanding of the relationship between the structure and function of HDM allergens. ProtParam predicted that the GRAVY score of Der f TEF 2 was −0.222 and the ProtScale prediction showed that the hydrophilic peptide chains were distributed throughout the amino acid sequence, and that there were significantly more hydrophilic than hydrophobic peptide chains. These tools showed that Der f TEF 2 is hydrophilic and soluble. The relative mutability indicates the probability that an amino acid is replaced by another amino acid. The relative mutability of Der f TEF 2 was found to have the highest score at residue 716. The accessible residues are the sum of the accessibility of the atoms, which, for Der f TEF 2, were predicted with maximum scores at residues 314, 315 and 316; thus, the active site is located on the surface of the protein.

Antigenic epitopes, also known as antigenic determinants, are specific antigenic sites that can be recognized by the corresponding antibody or antigen receptor and are the main chemical substances of immune system recognition ([@b36-mmr-20-06-5324]). According to the reverse vaccine method, the use of bioinformatics technology for T cell epitope prediction, and then effective immunological experiments to verify the bioinformatics results, not only ensures the accuracy of the results, but also can save the time and expense of generating synthetic peptides ([@b37-mmr-20-06-5324]).

To improve the accuracy of the predicted results, three different tools were used (BPAP, DNAStar Protean and BepiPred 1.0) to synthesize the data and identify the B cell epitopes of Der f TEF 2 (amino acids 29--35, 55--64, 92--99, 173--200, 259--272, 311--318, 360--365, 388--395, 422--428, 496--502, 512--518, 567--572, 580--586, 602--617, 785--790, 811--817 and 827--836). According to a previous study, asthma is a disease associated with genetic inheritance and the environment and HDM-induced asthma was associated with the HLA-DRB1\*0301 and HLA-DRB1\*0401 alleles ([@b38-mmr-20-06-5324]). Therefore, the alleles HLA-DRB1\*0301 and HLA-DRB1\*0401 were used to predict the T cell epitopes of the *D. farinae* allergen TEF 2. Based on the results of five algorithms (SYFPEITHI, NetMHCII 2.2 server, NetMHCIIpan-3.0, IEDB and Propred), 14 HLA-DRB1\*0301- and HLA-DRB1\*0401-restricted candidate T cell epitopes of Der f TEF 2 antigens were obtained (amino acid 1--15, 65--79, 120--134, 144--159, 236--250, 275--289, 404--418, 426--440, 463--477, 510--524, 644--658, 684--698, 716--730 and 816--830). The use of biotechnology to obtain recombinant allergens can provide novel insight and strategies for the development of specific immunotherapies and the treatment of allergic diseases.

In summary, the present study showed that TEF 2 exhibits high immunogenicity. The preset study also analyzed the structure and function of TEF 2 using bioinformatic technology, which may provide safe and sensitive reagents for the diagnosis and treatment of allergic diseases.
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![The cDNA of Der f TEF 2. (A) Agarose gel electrophoresis of products from the pET-32a-Der f TEF 2 double digest using *Bam*HI and *Eco*RI. Lanes: M, DNA Marker; 1 and 2, Der f TEF 2 DNA. (B) Amino acid sequences of Der f TEF 2. Der f, *Dermatophagoides farinae*; TEF 2, translation elongation factor 2.](MMR-20-06-5324-g00){#f1-mmr-20-06-5324}

![Analysis of the homologous alignment and phylogenetic relationship of Der f TEF 2. (A) Analysis of homologous alignment between Der f TEF 2 and other species. (B) Phylogenetic relationship of Der f TEF 2. Der f, *Dermatophagoides farinae*; TEF 2, translation elongation factor 2; Sar s, *Sarcoptes scabiei*; Rha z, *Rhagoletis zephyria*; *Gal o, Galendromus occidentalis*.](MMR-20-06-5324-g01){#f2-mmr-20-06-5324}

![Immunogenicity of recombinant TEF 2. (A) The protein band indicates the purified Der f TEF 2, M: protein Maker (kDa); 1: The recombinant Der f TEF 2 purified by affinity chromatography. (B) Western blotting indicated that recombinant TEF 2 binds to IgE in the sera from patients allergic to house dust mites. Lanes: M, protein marker (kDa); 1, purified recombinant TEF 2. (C) Specific IgE reactivity to TEF 2 was determined using ELISAs. P1-P3, serum from TEF 2-positive patients; C1-C2; serum from healthy controls. (D) IgE binding to extracts was inhibited by recombinant TEF 2. \*\*P\<0.01. TEF 2, translation elongation factor 2.](MMR-20-06-5324-g02){#f3-mmr-20-06-5324}

![Bioinformatics analysis using the predicted amino acid sequence of Der f TEF 2. The x-axis represents protein length from N- to C-terminal. The y-axis represents the score, with a higher score indicating higher probability. (A) Prediction of signal peptide cleavage sites. (B) Hydrophilic analysis of Der f TEF 2 protein. (C) Average flexibility of Der f TEF 2. (D) Relative mutability of Der f TEF 2 (E) Polarity/Zimmerman score of Der f TEF 2. (F) Accessible residues of Der f TEF2. Der f, *Dermatophagoides farinae*; TEF 2, translation elongation factor 2.](MMR-20-06-5324-g03){#f4-mmr-20-06-5324}

![Sequence and secondary structure analysis of the Der f TEF 2 allergen. In total, 27 α-helices and 6 β-sheets were identified in Der f TEF 2. B cell epitopes, T cell epitopes and phosphorylation sites were also indicated. Der f, *Dermatophagoides farinae*; TEF 2, translation elongation factor 2; T, T cell epitope; B, B cell epitope.](MMR-20-06-5324-g04){#f5-mmr-20-06-5324}

###### 

Results of skin prick tests.

                                Net wheal size (mm), level              
  ---- ----------- ------------ ---------------------------- ------ --- ----------
  1    Female/47   BA, AR, FA   4.5, ++                      8      0   0
  2    Female/37   AR           2.5, ++                      5      0   0
  3    Female/33                1.5, +                       5.75   0   0
  4    Male/24     BA, AR       2, +                           5    0   1.5, +
  5    Male/33     BA           10, +++                      6.5    0   0
  6    Male/36     AR           7.5, +++                     5      0   0
  7    Female/43   BA           3.5, ++                      5      0   0
  8    Female/51   BA, AR       2.5, ++                      4.5    0   0
  9    Female/18   BA, AR, DA   3.5, +++                     2      0   0
  10   Female/42   BA, AR, FA   3.5, ++                      5      0   2, +
  11   Female/47   BA, AR, FA   3, ++                        6      0   0
  12   Male/48     BA, AR       5.5, +++                     4.5    0   0
  13   Male/15     BA, AR       6, ++                        7.75   0   0
  14   Female/39   AR           12.5, +++                    8.5    0   0
  15   Male/63     BA, DA       8.5, +++                     8      0   0
  16   Male/15     BA, AR, FA   6.5, +++                     6      0   0
  17   Male/12     BA, AR       11, +++                      6      0   0
  18   Female/18   BA, AR       5.5, +++                     4.5    0   0
  19   Female/25   AR           6.5, +++                     6.5    0   0
  20   Female/40   BA, AR       6.5, +++                     5      0   0
  21   Male/75     BA, AR, FA   2.5, +                       6.5    0   0
  22   Male/11     BA, AR, DA   6.5, +++                     5.5    0   0
  23   Female/26   BA           1, +                         5.5    0   0
  24   Male/15     BA, AR, FA   7, ++                        8      0   2, +
  25   Female/14   BA, AR       6.5, +++                     6.5    0   0
  26   Male/8      BA, AR, FA   1, +                         4.5    0   0
  27   Female/43   BA           2, +                         4.5    0   0
  28   Male/47     BA, AR       3.5, ++                      5.5    0   0
  29   Male/45     AR           2, +                         7.5    0   0
  30   Female/52   AR, BA       1.5, +                       5.5    0   0
  31   Male/20     BA           1.5, +                       5      0   0
  32   Female/20   BA           2, +                         4      0   0
  33   Female/13   AR           1.25, +++                    6      0   2, +
  34   Female/86   BA, AR       9, +++                       5.5    0   2.75, ++
  35   Female/64   BA           2.25, +                      6      0   0
  36   Female/41   BA, AR       3.5, ++                      5.5    0   0
  37   Female/44   BA, AR       4.5, +++                     4.5    0   2, +

Positive (+), ≥1; Negative, 0. Level (+) indicates the relative fleck size compared with the histamine positive and PS negative controls: +++, the response was the same as or stronger than that of the histamine control; ++, the response was weaker than that of the histamine control but stronger than that of the negative control; +, the response was significantly weaker than that of the histamine control but slightly stronger than that of the negative control. R-Der f TEF 2, recombinant translation elongation factor 2 from *Dermatophagoides farinae*; BA, bronchial asthma; AR, allergic rhinitis; DA, drug allergy; MA, mango allergy; FA, food allergy; DME, dust mite extract; PS, physiological saline.

###### 

Protein subcellular localization.

  Support vector machine                           Localization     Reliability
  ------------------------------------------------ ---------------- -------------
  Amino Acid compartment                           Cytoplasmic      0.973
  N-peptide compartment                            Cytoplasmic      0.704
  Partitioned seq. compartment                     Cytoplasmic      0.854
  Physico-chemical compartment                     Cytoplasmic      0.373
  Neighboring seq. compartment CELLO Prediction:   Cytoplasmic      0.942
                                                   Cytoplasmic      3.847
                                                   Inner membrane   0.580
                                                   Periplasmic      0.442
                                                   Outer membrane   0.088
                                                   Extracellular    0.044

###### 

Functional sites or motifs in the allergen.

  Prediction tool   Functional sites or motifs                            Amino acid position
  ----------------- ----------------------------------------------------- ---------------------
  InterPro 5.0      P-loop containing nucleoside triphosphate hydrolase   4--345
                    Small GTP-binding protein domain                      20--174
                    Translation protein, β-barrel domain                  346--483
                    Translation elongation factor EFTu-like, domain 2     396--471
                    EFG domain III/V-like                                 486--561
                    Ribosomal protein S5 domain 2-type fold               563--727
                    Ribosomal protein S5 domain 2-type fold, subgroup     580--720
                    Translation elongation factor EFG/EF2, domain IV      608--723
                    Elongation factor EFG, domain V-like                  725--812
                    Tr-type G domain, conserved site                      58--73
  ScanProsite       Tr-type G domain profile(G_TR_2)                      17--348
                    Tr-type G domain signature(G_TR_1)                    58--73

EFTu, elongation factor thermo unstable; G domain, guanine nucleotide-binding domain; tr-type, translational-type.

###### 

Epitope prediction.

  Epitope, amino acid   Sequence           SYFPEITHI   NetMHCII   NetMHCIIpan   IEDB   Preprod
  --------------------- ------------------ ----------- ---------- ------------- ------ ---------
  1--15                 MVNFTVDEIRVLMNK    \+ +        \+ +       \+ +          \+ +   \+ +
  65--79                ERCITIKSTAISMYF    \+ +        \+ +       \+ +          \+ +   \+ +
  120--134              TAALRVTDGALVVVD    \+ +        \+ +       \+ +          \+ +   \+ +
  144--159              ETVLRQAIAERIKPVL   \+ +        \+ +       \+ +          \+ +   \+ +
  236--250              EKFKIDVDKLMNRL     \+ +        \+ +       \+ +          \+ +   \+ +
  275--289              FCMFVLDPIFKVFDA    \+ +        \+ +       \+ +          \+ +   \+ +
  404--418              SGIVASGQKVRIMGP    \+ +        \+ +       \+ +          \+ +   \+ +
  426--440              EDLVEKAIQRTVLMM    \+ +        \+ +       \+ +          \+ +   \+ +
  463--477              QFLVKTGTISTFKDA    \+ +        \+ +       \+ +          \+ +   \+ +
  510--524              LKRLAKSDPMVQCII    \+ +        \+ +       \+ +          \+ +   \+ +
  644--658              GPNLLVDVTKGVQYL    \+ +        \+ +       \+ +          \+ +   \+ +
  684--698              RGVRFNIHDVTLHAD    \+ +        \+ +       \+ +          \+ +   \+ +
  716--730              ACLLTAQPRLLEPV     \+ +        \+ +       \+ +          \+ +   \+ +
  816--830              RPYQIVMDTRKRKGL    \+ +        \+ +       \+ +          \+ +   \+ +

'++' means the final predicting regions of T cell epitopes in the Epitope prediction.

[^1]: Contributed equally
